ClinicalTrials.gg
CompletedNCT03371342Updated Mar 27, 2019

Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

A Phase 1 interventional study of Meditoxin and Botox in Overactive Bladder, sponsored by Medy-Tox. Completed at 1 site in Korea, Republic of. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-03-27.

Sponsored by Medy-Tox · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive — 3 open to participants now, 5 under way, 1 of them phase 3. botulinum toxin type A · Urinary Bladder, Overactive.

Enrollment
36th of 44
30 · median 84
Started
2017
the only one that year
Phase 1
3 of 44
none open now
Registered
31st of 44
by date
Lead sponsor
2 of 44
Medy-Tox

Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, this one is the 36th largest by enrollment, is the only one that started in 2017, is one of 3 in phase 1, and was the 31st registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, or all of them as a file.
02

Study summary

To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX

03

Conditions studied

  • Overactive Bladder
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female aged more than 20 years
  • Subject who has symptoms of Overactive Bladder for a period of at least 6 months immediately prior to screening

Exclusion criteria

Exclusion Criteria:

  • Patient not appropriate for participating in this study according to the investigator's opinion
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    MEDITOXIN

    Drug: Meditoxin

  • Active comparator
    BOTOX

    Drug: Botox

Interventions

  • Meditoxin (Botulinum toxin type A)

  • DrugBotox

    Botox(Botulinum toxin type A)

06

What researchers measure

Primary outcomes

  1. Change from baseline in adverse events of MEDITOXIN at 12 week

    safety profiles

    Time frame: baseline, week 12 follow up visits

Secondary outcomes

  1. Change from baseline in the daily average number of episodes of urinary incontinence

    Urinary incontinence recorded by the participants in a bladder diary during the 3 consecutive days prior to the study visit.

    Time frame: baseline, week 12 follow up visits

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in May 2018, 5 months.

Of 20 industry-sponsored phase 1 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 11. This study's 5 months is below that.

Counting every sponsor, half of 30 studies reached it within 9 months; a quarter within 4 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2017
First posted
Dec 13, 2017
StartActual
Dec 13, 2017
Primary completionActual
May 31, 2018
CompletionActual
Sep 5, 2018
Last update
Mar 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03371342
Lead sponsor
Medy-Tox
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Dec 13, 2017
Primary completion
May 31, 2018
Completion
Sep 5, 2018
Last update
Mar 27, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion